Join Genomind and guest speaker, Dr. Daniel Mueller, for a presentation on psychiatric pharmacogenetics (PGx). We review a variety of psychiatric medications, including antidepressants, antipsychotics and mood stabilizers, and discuss how PGx testing can assist in the evaluation of each medication group.
Dr. Daniel Mueller, MD, PhD is Head of the Pharmacogenetics Research Clinic at The Centre for Addiction and Mental Health (CAMH), which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).
Throughout his career, Dr. Mueller’s research goals have been to investigate genetic causes of response and side effects to psychiatric medications on which he published more than 200 articles. This line of research aims to significantly improve the treatment of psychiatric conditions and to lessen the burden of medication side effects and avoid adverse drug-drug interactions.
In this 1-hour session, Dr. Mueller leads a 45-minute presentation on psychiatric pharmacogenetics, then concludes with a 15-minute Q&A session.
Filmed October 28th, 2021
Are You Ready to Upgrade Your Practice with Genomind?
Genomind’s pharmacogenetic testing is the most advanced and comprehensive mental health pharmacogenetic test available. Get access to 24 genes related to mental health, 130+ medications, 10+ conditions, state-of-the-art tools, and 360 degrees of support today!
